stocks logo

CANF

Can Fite Biopharma Ltd
$
1.050
+0.005(+0.480%)
  • Overview
  • Forecast
  • Valuation
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.0833
Open
1.030
VWAP
1.05
Vol
58.26K
Mkt Cap
13.63M
Low
1.030
Amount
61.02K
EV/EBITDA(TTM)
--
Total Shares
4.99M
EV
9.44M
EV/OCF(TTM)
--
P/S(TTM)
11.78
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q3
150.00K
-23.47%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Can-Fite BioPharma Ltd. (CANF) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -32.69%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-32.69%
In Past 3 Month
1 Analyst Rating
up Image
328.57% Upside
Wall Street analysts forecast CANF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CANF is 4.50 USD with a low forecast of 4.50 USD and a high forecast of 4.50  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
up Image
328.57% Upside
Current: 1.050
sliders
Low
4.50
Averages
4.50
High
4.50
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-04-15
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-03-21
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-03-20
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-03-18
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-03-03
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-02-18
Reason

Valuation Metrics

The current forward P/E ratio for Can Fite Biopharma Ltd (CANF.A) is -2.32, compared to its 5-year average forward P/E of -0.75. For a more detailed relative valuation and DCF analysis to assess Can Fite Biopharma Ltd 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.75
Current PE
-2.32
Overvalued PE
4.22
Undervalued PE
-5.71

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.21
Current EV/EBITDA
0.11
Overvalued EV/EBITDA
0.82
Undervalued EV/EBITDA
-0.40

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
16.50
Current PS
0.00
Overvalued PS
30.82
Undervalued PS
2.19

Financials

Annual
Quarterly
FY2023Q4
YoY :
-21.32%
155.00K
Total Revenue
FY2023Q4
YoY :
-40.51%
-1.83M
Operating Profit
FY2023Q4
YoY :
-45.28%
-1.65M
Net Income after Tax
FY2023Q4
0.00
EPS - Diluted
FY2024Q4
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2024Q4
YoY :
-0.21%
-1.13K
FCF Margin - %
FY2024Q4
YoY :
+9.69%
-1.17K
Net Margin - %
FY2024Q4
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

CANF News & Events

Events Timeline

2025-05-05 (ET)
2025-05-05
08:19:52
Can-Fite raises $175M to date for namodenoson, piclidenoson development
select
2025-04-17 (ET)
2025-04-17
08:57:23
Can-Fite BioPharma says medical centers seek authorization for namodenoson
select
2025-04-14 (ET)
2025-04-14
14:31:29
Can-Fite BioPharma announces $3.0M registered direct offering of ADSs
select
Sign Up For More Events

News

8.5
05-05Newsfilter
Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
9.0
04-17Newsfilter
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
7.5
04-14Newsfilter
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
Sign Up For More News

FAQ

arrow icon

What is Can Fite Biopharma Ltd (CANF) stock price today?

The current price of CANF is 1.05 USD — it has increased 0.48 % in the last trading day.

arrow icon

What is Can Fite Biopharma Ltd (CANF)'s business?

arrow icon

What is the price predicton of CANF Stock?

arrow icon

What is Can Fite Biopharma Ltd (CANF)'s revenue for the last quarter?

arrow icon

What is Can Fite Biopharma Ltd (CANF)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Can Fite Biopharma Ltd (CANF)'s fundamentals?

arrow icon

How many employees does Can Fite Biopharma Ltd (CANF). have?

arrow icon

What is Can Fite Biopharma Ltd (CANF) market cap?